NCT06961071

Parathyroid Allotransplant for Treatment of Hypoparathyroidism

Parathyroid Allotransplant for Treatment of Hypoparathyroidism: PATTH

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 3 (estimated)
• Sponsor: Peter Stock · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is being done to see if transplanting parathyroid tissue into the forearm will help hypo-parathyroid patients achieve parathyroid hormone (PTH) levels that would help normalize their serum calcium and phosphorus levels. The parathyroid tissue used in this study will come from cadaveric tissues that were donated at the time of the death of the donor(s).

Detailed description

The company that makes the parathyroid hormone NATPARA will no longer be making the product by the end of 2024 which is one of the reasons the investigators are doing this study: to see if parathyroid transplantation is another way to treat hypoparathyroidism. This procedure is investigational and one of the first times the procedure is being done in humans. It is not approved by the FDA.

Conditions

• Hypoparathyroidism
• Hypoparathyroidism Postprocedural
• Hypoparathyroidism Post-surgical

Interventions

Type	Name	Description
BIOLOGICAL	Parathyroid Allotransplant	Parathyroid Allotransplant

Timeline

• Start date: 2026-01-15
• Primary completion: 2028-01-15
• Completion: 2028-01-15
• First posted: 2025-05-07
• Last updated: 2026-02-27

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study